Glucagon receptor agonists and antagonists affect the growth of the chick eye: a role for glucagonergic regulation of emmetropization?

PURPOSE In chicks, plus defocus retards eye growth, thickens the choroid, and activates glucagonergic amacrine cells, probably releasing glucagon. Glucagon receptor antagonists (expected to inhibit compensation to plus defocus) and agonists (expected to block myopia induction by form deprivation) were administered to eyes of chicks, to test the hypothesis that glucagon mediates the induction of changes in eye growth by plus defocus. METHODS Seven-day-old (P7) chick eyes were injected intravitreally with peptides at concentrations of approximately 10(-9) to 10(-5) M in 20 microL (injection volume). The glucagon-receptor antagonists [des-His(1),des- Phe(6),Glu(9)]-glucagon-NH(2) (des- Phe(6)-antagonist) and [des-His(1),Glu(9)]-glucagon-NH(2) (Phe(6)-antagonist) were administered daily for 4 to 5 days to plus-defocused eyes. Agonists (porcine glucagon-[1-29] and [Lys(17,18),Glu(21)]-glucagon-NH(2)) were monocularly administered daily for 5 days to form-deprived eyes. The contralateral eye remained open and received saline. After treatment, eyes were refracted, measured, and examined for histologic changes. RESULTS The Phe(6)-antagonist at 10(-5) M (in the syringe) inhibited changes in both refractive error and axial length compensation induced by +7-D lens wear; however, des-Phe(6)-antagonist (10(-5) M) had weak, inconsistent effects and did not antagonize the action of exogenous glucagon. Glucagon prevented ocular elongation and myopia and induced choroidal thickening in form-deprived eyes. [Lys(17,18),Glu(21)]-glucagon-NH(2) had little effect at 10(-7) M, but at 10(-6) to 10(-5) M altered rod structure and inhibited eye growth. CONCLUSIONS Exogenous glucagon inhibited the growth of form-deprived eyes, whereas Phe(6)-antagonist inhibited compensation to plus defocus, as might be expected if glucagon is an endogenous mediator of emmetropization. The reason for the failure of des-Phe(6)-antagonist to counteract the effects of exogenous glucagon requires further investigation.

[1]  B. Ehinger,et al.  Glucagon immunoreactive neurons in the retina of different species , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.

[2]  W. Stell,et al.  Glucagon- and secretin-related peptides differentially alter ocular growth and the development of form-deprivation myopia in chicks. , 2005, Investigative ophthalmology & visual science.

[3]  P. Luthert,et al.  Glial remodeling and neural plasticity in human retinal detachment with proliferative vitreoretinopathy. , 2005, Investigative ophthalmology & visual science.

[4]  Earl L. Smith,et al.  Image defocus modulates activity of bipolar and amacrine cells in macaque retina. , 2004, Investigative ophthalmology & visual science.

[5]  F. Schaeffel,et al.  Effects of positive and negative lens treatment on retinal and choroidal glucagon and glucagon receptor mRNA levels in the chicken. , 2004, Investigative ophthalmology & visual science.

[6]  W. Stell,et al.  Variable effects of previously untested muscarinic receptor antagonists on experimental myopia. , 2003, Investigative ophthalmology & visual science.

[7]  D. Drucker,et al.  International Union of Pharmacology. XXXV. The Glucagon Receptor Family , 2003, Pharmacological Reviews.

[8]  F. Schaeffel,et al.  Evidence for a potential role of glucagon during eye growth regulation in chicks , 2002, Visual Neuroscience.

[9]  Kathy A. Lencses.  Glucagon amacrine cells regulate ocular growth and refraction in chick , 2002 .

[10]  F. Schaeffel,et al.  Defocus-induced changes in ZENK expression in the chicken retina. , 2002, Investigative ophthalmology & visual science.

[11]  D. Drucker,et al.  The Glucagon Receptor Family , 2000 .

[12]  Frank Schaeffel,et al.  Light- and focus-dependent expression of the transcription factor ZENK in the chick retina , 1999, Nature Neuroscience.

[13]  W. Stell,et al.  Immunocytochemical characterization of quisqualic acid‐ and N‐methyl‐D‐aspartate‐induced excitotoxicity in the retina of chicks , 1998, The Journal of comparative neurology.

[14]  J. Wallman,et al.  Visual influences on diurnal rhythms in ocular length and choroidal thickness in chick eyes. , 1998, Experimental eye research.

[15]  V. Hruby,et al.  Pure Glucagon Antagonists: Biological Activities and cAMP Accumulation Using Phosphodiesterase Inhibitors , 1997, Peptides.

[16]  M. Edwards,et al.  Animal models of myopia. A review. , 2009, Acta ophthalmologica Scandinavica.

[17]  V. Hruby,et al.  Low level cyclic adenosine 3',5'-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists. , 1996, Endocrinology.

[18]  R. Weiler,et al.  Quantitative anatomy, synaptic connectivity and physiology of amacrine cells with glucagon-like immunoreactivity in the turtle retina , 1996, Journal of neurocytology.

[19]  T. Fujikado,et al.  ERG of form deprivation myopia and drug induced ametropia in chicks. , 1996, Current eye research.

[20]  Earl L. Smith,et al.  Spectacle lenses alter eye growth and the refractive status of young monkeys , 1995, Nature Medicine.

[21]  S. Crewther,et al.  Formoguanamine-induced inhibition of deprivation myopia in chick is accompanied by choroidal thinning while retinal function is retained , 1995, Vision Research.

[22]  W. Stell,et al.  The effect of vasoactive intestinal peptide on development of form deprivation myopia in the chick: a pharmacological and immunocytochemical study , 1995, Vision Research.

[23]  W. Stell,et al.  Basic fibroblast growth factor (bFGF) and transforming growth factor beta (TGF-beta) act as stop and go signals to modulate postnatal ocular growth in the chick. , 1994, Experimental eye research.

[24]  S. Judge,et al.  Ocular development and visual deprivation myopia in the common marmoset (Callithrix jacchus) , 1993, Vision Research.

[25]  W. Stell,et al.  Apomorphine blocks form-deprivation myopia in chickens by a dopamine D2-receptor mechanism acting in retina or pigmented epithelium , 1993, Visual Neuroscience.

[26]  A. Laties,et al.  Muscarinic antagonist effects on experimental chick myopia. , 1991, Experimental eye research.

[27]  A. Fernandez-cruz,et al.  Identification of Glucagon Receptors in Rat Retina , 1990, Journal of neurochemistry.

[28]  R. B. Merrifield,et al.  Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist , 1989, Peptides.

[29]  A. Laties,et al.  Retinal dopamine and form-deprivation myopia. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Drucker,et al.  Glucagon gene expression in vertebrate brain. , 1988, The Journal of biological chemistry.

[31]  T. Wiesel,et al.  Increase in retinal vasoactive intestinal polypeptide after eyelid fusion in primates. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[32]  V. Hruby,et al.  Long-Acting Oxytocin Antagonists: Effects of 2-D-Stereoisomer Substitution on Antagonistic Potency and Duration of Action 1 , 1987, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[33]  V. Hruby,et al.  Activation of two signal-transduction systems in hepatocytes by glucagon , 1986, Nature.

[34]  R. Ekman,et al.  Glucagon and VIP in the retina. , 1985, Investigative ophthalmology & visual science.

[35]  B. Pansky,et al.  Glucagon-like immunoreactivity in mouse and rat retina , 1985, Neuroscience Letters.

[36]  P. Hof,et al.  The effects of VIP on cyclic AMP and glycogen levels in vertebrate retina , 1984, Peptides.

[37]  M. Millodot,et al.  Retinoscopy and Eye Size , 1970, Science.